| 000 | 01960cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030922.0 | ||
| 008 | 140104s2013 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.09.M.Sc.2013.Ah.F | ||
| 100 | 0 | _aAhmed Salah Eldin Mohamed Salem | |
| 245 | 1 | 0 |
_aFrequency of aspirin resistance clopidogrel resistance in patients with coronary artery disease and its clinical significance / _cAhmed Salah Eldin Mohamed Salem ; Supervised Amr Elhadidy , Amal Rizk , Mohammed Eldesuky |
| 246 | 1 | 5 | _aمعدل حدوث المقاومة ضد عقارى الأسبرين و الكلوبيدوجريل لمرضى قصور الشرايين التاجية و مغزاها الإكلينيكى |
| 260 |
_aCairo : _bAhmed Salah Eldin Mohamed Salem , _c2013 |
||
| 300 |
_a195 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Critical Care Medicine | ||
| 520 | _aAspirin and clopidogrel are important components of medical therepy for patients with cardiovascular or cerebrovascular diseases. Despite their use, a significant number of patients experience recurrent adverse ischemic events. Interindividual variability of platelet aggregation in response to these antiplatelet agents may be an explanation for some of these recurrent events, and small trials have linked aspirin and/or clopidogrei resistance, as measured by platelet function tests, to adverse events | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAspirin resistance | |
| 653 | 4 | _aClopidogrel resistance | |
| 653 | 4 | _aCoronary artery disease | |
| 700 | 0 |
_aAmal Rizk , _eSupervisor |
|
| 700 | 0 |
_aAmr Elhadidy , _eSupervisor |
|
| 700 | 0 |
_aMohammed Ibrahim Eldesuky , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c44699 _d44699 |
||